After 14 days of treatment, 64.6% of the patients taking ... More information: Jun Hamano et al, Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind ...

Naldemedine is efficacious for preventing opioid-induced constipation and for improving QOL among individuals with cancer.

Exclusion criteria included fecal impaction, mechanical bowel obstruction, constipation not attributed to postprocedure opioid use, calculated creatinine clearance less than 50 mL/min, and ...

naldemedine use was associated with constipation prevention and a significant improvement of constipation-related quality of life (QOL) in cancer patients initiating opioid pain therapy. Along with ...

Here, we report the preventive effect of naldemedine versus placebo for constipation in patients with cancer starting an opioid therapy in a multicenter ... We conducted rigorous safety assessments on ...

Patients with cancer starting a first-time regularly dosed strong opioid for cancer pain and age 20+ years were included. Eligible patients were randomly assigned to the naldemedine (Symproic 0.2 mg) ...

Constipation is common among people ... targeted therapy such as a peripheral opioid antagonist — hold promise for treatment of one of the most common and troublesome side effects of chronic ...

However, 77% of opioid treatment programs treat Medicare enrollees, unlike just 28% of office-based buprenorphine providers, though these programs are less common, the report (PDF) showed.